Evommune Shares Plunge After Second Clinical Trial Failure for EVO756

Shares of Evommune (EVMN) plunged in pre-market trading Wednesday after the clinical-stage biotechnology company announced that its experimental drug, EVO756, failed a mid-stage clinical trial for atopic dermatitis.

Trial Fails to Meet Endpoints

Evommune reported after Tuesday's market close that EVO756, an oral MRGPRX2 antagonist, did not meet its primary or secondary endpoints at any dose in a Phase 2b study. The randomized, double-blind, placebo-controlled trial involved 121 adults with moderate-to-severe atopic dermatitis over a 12-week treatment period.

Following the results, the Palo Alto-based company stated it will not advance the development of EVO756 for this indication. However, Evommune intends to continue a separate Phase 2b trial for the compound as a potential treatment for migraine prophylaxis.

A Pattern of Setbacks

This marks the second significant clinical failure for EVO756 in 2026. Earlier this year, the drug also missed its primary endpoint in a Phase 2b trial for chronic spontaneous urticaria, leading Evommune to halt that program entirely.

Ad

With two of EVO756's potential applications now shelved, the company's near-term pipeline value increasingly relies on its other candidates. These include EVO301, an IL-18 binding protein fusion candidate in Phase 2b development for atopic dermatitis and ulcerative colitis, and the remaining EVO756 study for migraine.

Market Impact

The news triggered a sharp sell-off in the company's stock, which fell 16.4% to $10.93 in pre-open trading. The decline pushed the shares toward their 52-week low of $10.47, erasing much of a recent recovery.

A broader risk-off sentiment in U.S. markets likely amplified the pressure on Evommune's shares. Major indices were trading lower amid concerns over rising oil prices and elevated Treasury yields ahead of key inflation data due later in the week.